Extended Data Fig. 7: Survival of cohorts based on supertype and motif neoepitopes. | Nature Cancer

Extended Data Fig. 7: Survival of cohorts based on supertype and motif neoepitopes.

From: Mutational landscape influences immunotherapy outcomes among patients with non-small-cell lung cancer with human leukocyte antigen supertype B44

Extended Data Fig. 7

Survival estimated using the Kaplan-Meier method. Survival curves of B27-(motif) absent patients are depicted in red, B27-motif (present) in blue, B27/B44-motif (present) in green, B44-(motif) absent in dark purple, B44-motif (present) in orange, other in light purple. Note given the rarity of B27/B44-motif absent patients (none in UCLA and DF-melanoma cohorts), a separate category was not created and these patient(s) were grouped as B44-(motif) absent. a, UCLA NSCLC cohort overall survival. Median survival times, longest to shortest (months): B27-motif present (not reached), B27/B44-motif present (18.7), other (18.2), B44-motif present (16.2), B44-motif absent (11.6), B27-motif absent (11.5). b, UCLA NSCLC cohort progression-free survival. Median survival times, longest to shortest (months): B27/B44-motif present (49.5), B27-motif present (44.7), other (10.6), B27-motif absent (8.2), B44-motif present (4.9), B44-motif absent (2.0). c, DF-NSCLC cohort overall survival. Median survival times, longest to shortest (months): B27/B44-motif present (not reached), B27-motif present (not reached), B44-motif present (not reached), B44-motif absent (not reached), other (13.4), B27-motif absent (8.4). Note 2 B27/B44-motif absent patients grouped with B44-motif absent (this group did not exist in other cohorts). d, DF-NSCLC cohort progression-free survival. Median survival times, longest to shortest (months): B27/B44-motif present (32.8), B27-motif present (not reached), B44-motif present (14.5), B44-motif absent (4.22), B27-motif absent (4.2), other (2.8). Note 2 B27/B44-motif absent patients grouped with B44-motif absent (this group did not exist in other cohorts). Not all patients had censoring data available leading to fewer patients in each category compared to DF-NSCLC OS. e, DF-melanoma cohort overall survival. Median survival times, longest to shortest (months): B27/B44-motif present (48.6), B44-motif present (34.5), B27-motif present (26.3), B44-motif absent (23.8), other (10.3), B27-motif absent (5.3). f, DF-melanoma cohort progression-free survival. Median survival times, longest to shortest (months): B44-motif present (19.6), B27-motif present (15.0), B27/B44-motif present (11.0), B27-motif absent (3.7), other (3.5), B44-motif absent (3.3).

Source data

Back to article page